Anti-inflammatory effect of Chang-An-Shuan on TNBS-induced experimental colitis in rats
© The Author(s). 2017
Received: 3 May 2016
Accepted: 15 May 2017
Published: 15 June 2017
Inflammatory bowel disease (IBD), denominated by Crohn’s disease and ulcerative colitis, is often associated with abdominal pain, diarrhea and bloody stool. The standard protocols for treating colitis conditions are not satisfactory; thus, complementary and alternative medicines have been increasingly accepted by IBD sufferers worldwide. In this study, we aimed to elucidate the anti-inflammatory effect of Chang-An-Shuan (CAS), a 6-herb Chinese medicinal formula, on 2, 4, 6-trinitrobenzenesulfonic acid (TNBS)-induced colitis in rats and the underlying mechanisms.
Sprague-Dawley rats were administered with rectal gavage of 2.5% TNBS in 50% ethanol for the induction of experimental colitis which is considered as a model for Crohn’s disease. Upon the TNBS induction, rats were given CAS at 0.5 g/kg/day or 5 g/kg/day for 10 days. The application of salicylazosulfapyridine (0.5 g/kg/day) was served as a positive reference drug for the colitis condition. The efficacy and mechanistic action of CAS were evaluated by means of histopathological and biochemical approaches such as histological staining, real-time polymerase chain reaction, Western blotting analysis and enzyme-linked immunosorbent assay.
Oral administration of CAS at 5 g/kg/day, but not 0.5 g/kg/day, significantly ameliorated the severity of TNBS-induced colitis as evidenced by the reduced loss of body weight, alleviated diarrhea and decreased bloody stool. While lowering the disease activity index, the administration of CAS lessened mucosal lesions thus mucosal integrity of the colitis rats was notably improved. Further, the CAS treatment also significantly suppressed the mRNA and protein levels of pro-inflammatory cytokines, namely interleukin-1β and tumor necrosis factor-α while enhancing the level of anti-inflammatory cytokine IL-10 in the TNBS-treated rats. Importantly, the ameliorative effect of CAS was related to an inhibition of the nuclear factor-κB (NF-κB) signaling pathway by downregulating the expression levels of NF-κBp-65, p-38 and p-AKT.
We suggest that CAS is a potential alternative remedial approach for treating IBD conditions, and the anti-inflammatory effect of CAS is associated with the down-regulation of the NF-κB signaling pathway and the balanced production of pro- and anti-inflammatory cytokines.
KeywordsChang-An-Shuan Ulcerative colitis Interleukin-1β Tumor necrosis factor-α Nuclear factor-κB
Inflammatory bowel disease (IBD), denominated by Crohn’s disease (CD) and ulcerative colitis (UC), is an immune-mediated chronic intestinal disorder characterized by rectal bleeding, mucous stool and diarrhea, in which epithelial barrier disruption and mucosal ulceration are associated . The mainstay therapies for colitis include anti-inflammatory drugs, 5-aminosalicylic acid and glucocorticosteroids, and immunomodulatory agents, azathioprine, mercaptopurines and cyclosporine . However, these drugs are unsatisfactory as repeated relapses and serious side effects often occur. Indeed, the drug-induced toxicity appears to be a continuous challenge. Over the past decades, though substantial progress has been made to treat this debilitating disease, effective therapies are yet available. Although the exact etiologies of colitis remain unknown, it is generally accepted that IBD is an autoimmune disease with an initial defect in sampling gut luminal antigens, or a mucosal susceptibility that leads to the activation of immune responses. In consequence, the overproduction of pro-inflammatory mediators from immune cells, such as reactive oxygen species, nitrogen metabolites and pro-inflammatory cytokines, result in mucosal damage and the sustenance of inflammatory responses  . According to a number of studies, we acknowledged that various kinds of intestinal immune cells play important roles in the initiation of IBD; however, activated CD4+ T helper (Th) cells, explicitly Th1 and Th2, are definitely responsible for the maintenance of the inflammatory condition s of CD and UC . It is established that CD is generally considered as a Th1 cytokine-mediated disorder whereas UC appears to be likely arisen from Th2-mediated responses. Nevertheless, some other new subsets of Th cells have also been suggested to induce the IBD pathologies . Upon the intrinsic generation of different inflammatory mediators and their release into the bloodstream, tissue injury and/or epithelial damage are observed as the disrupted mucosal homeostasis, tissue injury and/or epithelial damage are observed as the disrupted mucosal homeostasis in IBD. Among these pro-inflammatory mediators, the pro-inflammatory cytokines, particularly tumor necrosis factor α (TNF-α), interleukin (IL)-1β, IL-6, IL-12 and IL-23 are believed to play crucial roles in the pathogenesis of IBD [7–9]. Therefore,the regulation of these cytokines has been proposed as a strategy to treat IBD . In this regard, anti-inflammatory drugs, aminosalicylates and corticosteroids, and immunosuppressive agents, are considered as the first-line therapies for IBD patients . As mentioned earlier, undesired side effects are often arisen from these mainstream pharmaceuticals, the recrudescence rates of IBD stay relatively high [12, 13]. Therefore, the use of complementary and alternative (CAM) approaches has been increasingly appreciated by the sufferers in the management of colitis.
In recent years, traditional Chinese medicine (TCM) has been considered as one of the most popular CAM approaches for IBD patients as the bioactivities of a variety of TCM herbs have been validated by bench-to-bedside studies. Intriguingly, the application of medicinal formulations, which are mixtures of herbs or phytocompounds that influence multiple systems in the body, has been shown with preferential effect over the individual conventional treatment protocols for IBD sufferers indicating that herbal medicine can be a promising alternative approach for the management of colitic conditions , and several medicinal formulas comprising Chinese herbs have been demonstrated effective against IBD .
According to the Chinese medical theory, the symptoms of UC are derived from the imbalance of Qi accompanied with dampness or cold-dampness in the spleen and intestine. BaiTouWeng decoction (BTWD) is a traditional Chinese herbal recipe for invigorating the intestine and restoring the imbalance of Qi that has been prescribed in TCM clinics for many years. To the traditional BTWD, we added in the following herbal medicines: HerbaPogostemonis, Herba Centellat and, indigo naturalis, and we named this modified formula Chang-An-Shuan (CAS). In detail, our formula CAS comprises: Pulsatilla chinensisRegel (root of Pulsatilla Adans, family: Ranunculaceae), Cortex Fraxini (bark of Fraxinus chinensis Roxb, family: Oleaceae), RhizomaCoptidis (rhizome of Coptis chinensis Franch, family: Ranunculaceae), HerbaPogostemonis [leaf and stem of Pogostemon cablin(Blanco) Benth, family: Lamiaceae], Herba Centellat [leaf ofCentella asiatica (L.) Urban, family: Umbelliferae], and indigo naturalis[extractive of Baphicacanthus cusia (Nees) Bremek, family: Acanthaceae]. Recently, Dai et al. reported that BTWD-based Chinese medicine formula could greatly improve the clinical symptoms of patients with acute period of left hemicolon type-UC . According to the TCM clinical experience, several ingredients of the CAS formulation are useful for some common gastrointestinal ailments , including nausea, vomiting, diarrhea and abdominal cramps. However,no scientific evidence of efficacy or mechanistic action of CAS on experimental colitis has been provided. Therefore, in this study, we aimed to assess the anti-inflammatory effect of CAS on 2, 4, 6-trinitrobenzenesulfonic acid (TNBS)-induced colitis in rats, and to elucidate the underlying mechanisms of its in vivo activities.
Male Sprague-Dawley rats aged 8–10 weeks old weighing 180 ± 40 g were obtained from the Centre of Medical Experimental Animals of Guangdong [Certificate of quality: SCXK (Yue) 2008–0002]. Rats were housed in standard laboratory cages at the Experimental Animal Center of Guangzhou University of Chinese Medicine [Center-Certificate of quality: SCSK (Yue) 2013–0002]. The rats were given access to standard diet and autoclaved distilled water ad libitum. The housing laboratory was set with 12-h (h) light/dark cycles, the cages were ventilated, and the environment was clean and quiet. The room temperature was maintained at 22 ± 1 °C. All handling of animals and experimental procedures were conducted consistent with the institutional guidelines of the Ethics Committee of the Experimental Animal Center of Guangzhou University of Chinese Medicine, China (TCM F1–2015029).
Salicylazosulfapyridine (SASP) was supplied by Sunve Pharmaceutical Co. Ltd. (China, cat#20130117). TNBS was obtained from Sigma Chemical Co. Ltd. (USA, cat#1001616585). ELISA kits for rat IL-1β, IL-10 and TNF-α were purchased from Wuhan Biological Engineering Co. Ltd. (China, cat#U20017513 and CSB-E08855r; cat#U20017514; cat#V18017512 and CSB-E11987r). RNAiso Plus kit was from TaKaRa Technologies Co. Ltd. (China, cat#D9108A). SYBR®Premix Ex Taq™ (TliRNaseH Plus) was purchased from Invitrogen Life Technologies Co. Ltd. (USA, cat#DRR820A). Reverse Transcriptase M-MLV (RNase H-) reagent was purchased from TaKaRa Technologies Co. Ltd. (China, cat#RR036). Anti-p38 antibody was obtained from Abcam Co. Ltd. (USA, cat#ab27986);Anti-nuclear factor-κB(NF-κB) p65 (D14E12) XP® Rabbit mAb was from Cell Signaling Technology (USA, cat#8242S);Anti-phospho-AKT (Ser473, D9E) XP® Rabbit mAb was purchased from Cell Signaling Technology (USA, cat#4060S).
Tecan Sunrise (TECAN technologyCo. Ltd. Austria); TP800 Real-time PCR machine (BIO-RAD Co. Ltd. USA); NiconFluorescent electronic microscope (Nikon Co. Ltd. Japan); BIO-RAD electrophoresis (BIO-RAD Co. Ltd. USA); 721BRO4320 MultiImager machine (BIO-RAD Co. Ltd. USA).
Preparation of CAS extract
The composition of CAS
Pulsatilla chinensis Regel
Bai Tou Weng
Ji Xue Cao
Induction of acute colitis and drug intervention
Rats were randomly divided into control group, TNBS group, SASP group and CAS groups, starved for 12 h, and lightly anesthetized with 10% chloral hydrate by an intraperitoneal route. Then a flexible polyethylene catheter with an external diameter of 2 mm was inserted rectally into the colon of the rat. The tip was 6–8 cm proximal to the anus verge . To the TNBS group (n = 10), SASP group and CAS groups, 2.5%TNBS dissolved in 50% ethanol solution (w/v) was instilled into the colon via a cannula (125 mg/kg) for the induction of acute colitis. To the control group (n = 10), the same volume of ethanol solution without TNBS was instilled. Rats were held in a head-down position for 2–3 min after the instillation for a better distribution of the agent in the entire colon. Upon the TNBS induction, drug intervention (CAS or SASP) was orally administered to rats for 10 days (d). SASP was used as a positive reference drug for colitis. The SASP group (n = 10) was treated with SASP at 0.5 g/kg/d whereas the control group were fed with normal saline. CAS extract was given to rats at either 5 g/kg/d (n = 10) or 0.5 g/kg/d (n = 10).
Blood was collected from rats and serum was obtained after centrifugationat 3500×g for 10 min. Then, the rats were sacrificed. Colonic segments were excised, freed from adherent adipose tissue, rinsed with saline to remove fecal residue and blotted dry. The length of each colon sample was measured. The colon tissues were collected for protein and RNA extraction.
Disease activity index (DAI)
The DAI of model rats was taken from day 3 till the last day of the experimental period. The index was assessed based on three variables, including the change of body weight, stool consistency, and bleeding, in accordance with a previously reported method .
Histological examination of colonic tissue
When rats were sacrificed, distal colons were harvested, rinsed and fixed in 4% paraformaldehyde at 4 °C overnight. Colonic tissues were then processed with sequential clearing and dehydrating steps, and embedded in paraffin blocks. Samples were sectioned into 6 μm slices and subjected to standard Hematoxylin and Eosin (H&E) staining for the evaluation of colonic architecture, loss of crypts, extent of injury and mucosal damage and lymphocyte infiltration.
Measurement of serum and colonic cytokine levels
The blood samples were centrifuged at 3500×g for 10 min and serum was obtained. The colon samples were collected by the same location and quality. Serum and colon samples were stored at −80 °C until assayed. Levels of IL-1β, TNF-α and IL-10 were measured with enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer’s instructions. All samples were assayed in duplicate.
Western blotting analysis
Frozen proximal and distal colon specimens were homogenized in extraction buffer, which contained 50 mmol/L Tris-HCl (pH 8.0), 150 mmol/L NaCl, 1% Triton X-100, 0.02% sodium azide, 1 μg/mL aprotinin and 100 μg/mL phenylmethylsulfonyl fluoride (PMSF). The homogenates were centrifuged at 12000×g for 10 min at 4 °C, and protein concentration in the supernatant was quantified by bicinchoninic acid method. 60 μg of proteins were separated using 10% or 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and the separated proteins were then transferred electrophoretically onto nitrocellulose membranes. After blocking the non-specific binding sites with 5% non-fat dry milk in Tris buffered saline (TBS) for 1 h, the membranes were then incubated with primary antibodies against p-38 (1:1000), p-AKT (1:1000), NF-κB p-65 (1:1000) or β-actin (1:500) respectively overnight at 4 °C. The β-actin loading was served as the internal control. The membranes were then washed with TBS with 0.1% Tween-20 (TBST) three times and incubated with appropriate secondary antibody for 1 h at room temperature. Detection of protein was achieved by enhanced chemiluminescence agent, and the blot was subjected to autoradiography.
Real-time quantitative polymerase chain reaction (qPCR)
List of primer sequences for qPCR
Data are expressed as the means ± standard error of mean (S.E.M.). *P < 0.05, vs. control group; #P < 0.05, vs. TNBS group. Statistical analysis was performed using the SPSS 19.0 statistical software. The parameters were evaluated by one-way analysis of variance (ANOVA) followed by LSD-t test. P-values less than 0.05 were considered statistically significant.
CAS decreased DAI scores in TNBS-induced colitis in rats
Histological examination of colonic tissues
Serum levels of IL-1β, IL-10 and TNF-α
The serum levels of cytokines in different experimental groups
186.99 ± 28.89
113.91 ± 17.05
2.9578 ± 1.37
271.33 ± 88.19*
147.34 ± 59.03*
2.2006 ± 0.56*
SASP (0.5 g/kg)
176.82 ± 25.42 #
112.97 ± 38.77 #
1.5980 ± 0.55 #
CAS (5 g/kg)
216.57 ± 20.28 #
118.63 ± 31.12 #
2.8371 ± 1.10
CAS (0.5 g/kg)
224.98 ± 54.92
122.19 ± 17.35
2.2244 ± 0.57
Colon levels of IL-1β and TNF-α
The expression levels of NF-κB p-65, p38 and p-AKT
mRNA expression of pro-inflammatory cytokines in colonic tissues
Animal models of intestinal inflammation are frequently used for studying the pathogenesis of human IBD . For instance, TNBS-, acetic acid- and dextran sulfate sodium-induced colitis models have been developed to help elucidate the pathogenic and molecular mechanisms of human IBD . Similar to other chemically induced colitis models, TNBS is a chemical agent commonly used to induce colonic inflammation in the gut of rodents. The TNBS-induced colitis is characterized by several clinical and histopathological features resembling those of human IBD . Generally, TNBS-induced colitis has been regarded a model for aninmal colitis as transmural granulomatous inflammation associated with diarrhea, rectal prolapse, weight loss and colonic wall thickening are observed , and is very suitable to study anti-inflammatory agents during the course of developing and resolving inflammation . In the current study, CAS significantly improved the recovery of body weight loss and reduced DAI scores in TNBS-induced rats indicating that CAS, a TCM herbal formula, exerts a potent protective effect against mucosal inflammation. This study confirmed the efficacy of CAS in an experimental colitis that was associated with an inhibition of the NF-κB signaling pathway.
Although the etiology of IBD is not completely understood, it is well accepted that the imbalance between pro-inflammatory cytokines, such as TNF-α, IFN-γ, IL-1β, IL-6 and IL-12, and anti-inflammatory cytokines, namely IL-4, IL-5 and IL-10, plays a central role in the modulation of inflammatory processes [25–27]. Previous reports demonstrated that inflamed mucosa from UC patients have shown increased expression of certain pro-inflammatory cytokines such as IL-1β, IL-6 and TNF-α [26, 27]. In this study, the application of CAS significantly suppressed the production of IL-1β and TNF-α meanwhile the level of anti-inflammatory cytokine IL-10 was enhanced. To this end, the protective effect of CAS against colitis was plausibly related to its maintenance of a relative balance between pro-inflammatory and anti-inflammatory cytokines. As such, mucosal inflammation was alleviated, so as the development of IBD symptoms.
NF-κB activation is believed to be a pivotal mediator of a number of inflammatory processes as well as other vital cellular responses. The enhancement of the NF-κB subunit p65 was an indication of the activation of NF-κB . In the TNBS-induced rats, NF-κB activation was significantly up-regulated . Our result was in agreement with previous findings that NF-κB activation plays a critical role in most immune and inflammatory processes including the etiology of IBD . Importantly, the application of CAS notably reduced the expression level of NF-κB p65. Taken together, the anti-inflammatory effect of CAS on the development of TNBS-induced colitis was related to the inhibition of the NF-κB signaling pathway. On the other hand, the PI3K-dependent AKT phosphorylation is considered as a NF-κB crosstalk signaling. Indeed, AKT is a serine/threonine kinase that is a direct downstream target of PI3K . The phosphorylation of AKT generates a positive feedback in the maintenance of inflammation by activating transcriptional factors, such as NF-κB, which is a key regulator of gene transcription of various pro-inflammatory cytokines [32, 33]. The inhibition of AKT phosphorylation was therefore implicated in reducing colonic damage in IBD patients . Our Western blotting result showed that AKT phosphorylation was suppressed in TNBS-treated rats, though not in a significant manner, by administration of CAS. As long as the AKT phosphorylation was not enhanced, the severity of TNBS-colitis was ameliorated. Collectively, the present study demonstrated that CAS attenuates systemic inflammatory responses via an inhibition of NF-κB activity in rats with TNBS-induced colitis. With such anti-inflammatory effect provided, we suggest that CAS is potentially a remedy for attenuating the pathological conditions in IBD.
Taken together, the results reported here show that CAS is a potential alternative remedial approach for treating IBD conditions, and the anti-inflammatory effect of CAS is associated with the down-regulation of the NF-κB signaling pathway and the balanced production of pro- and anti-inflammatory cytokines.
The authors are grateful for the help from the First School of Clinic Medicine, Guangzhou University of Chinese Medicine. This work was supported by the Project of National Key Subject for Chinese medicine (YueCaiJiao No. 2014-276), the Foundation of Center Finance for Supporting University Developing in Guangdong.
FL designed the experiment protocol. HM and H-wL preceded all animal experiments. HM, H-wL, J-tH and P-wL were responsible for the targets detecting processing. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- da Silva MS, Sanchez-Fidalgo S, Talero E, Cardeno A, da Silva MA, Villegas W, Souza Brito AR, de La Lastra CA. Anti-inflammatory intestinal activity of Abarema cochliacarpos (Gomes) Barneby & Grimes in TNBS colitis model. J Ethnopharmacol. 2010;128(2):467–75.View ArticlePubMedGoogle Scholar
- Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol: WJG. 2008;14(3):354–77.View ArticlePubMedPubMed CentralGoogle Scholar
- Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3(7):390–407.View ArticlePubMedGoogle Scholar
- Yao J, Wang JY, Liu L, Li YX, Xun AY, Zeng WS, Jia CH, Wei XX, Feng JL, Zhao L, et al. Anti-oxidant effects of resveratrol on mice with DSS-induced ulcerative colitis. Arch Med Res. 2010;41(4):288–94.View ArticlePubMedGoogle Scholar
- Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3(7):521–33.View ArticlePubMedGoogle Scholar
- Fouser LA, Wright JF, Dunussi-Joannopoulos K, Collins M. Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol Rev. 2008;226:87–102.View ArticlePubMedGoogle Scholar
- Ebrahimi Daryani N, Najmi Varzaneh F, Hedayat M, Taher M, Farhadi E, Mahmoudi M, Nicknam MH, Bashashati M, Rezaei N. Interleukin-23 receptor single nucleotide polymorphisms in ulcerative colitis. A study in Iranian populations. Clin Res Hepatol Gastroenterol. 2014;38(3):360–5.View ArticlePubMedGoogle Scholar
- Lee MJ, Lee JK, Choi JW, Lee CS, Sim JH, Cho CH, Lee KH, Cho IH, Chung MH, Kim HR, et al. Interleukin-6 induces S100A9 expression in colonic epithelial cells through STAT3 activation in experimental ulcerative colitis. PLoS One. 2012;7(9):e38801.View ArticlePubMedPubMed CentralGoogle Scholar
- Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012;380(9853):1606–19.View ArticlePubMedGoogle Scholar
- Yadav V, Varum F, Bravo R, Furrer E, Bojic D, Basit AW. Inflammatory bowel disease: exploring gut pathophysiology for novel therapeutic targets. Transl Res. 2016;176:38–68.View ArticlePubMedGoogle Scholar
- Yoshino T, Sono M, Yazumi S. Usefulness of sulfasalazine for patients with refractory-ulcerative colits. BMJ Open Gastro. 2016;3(1):e000103.View ArticleGoogle Scholar
- Abdallah DM, Ismael NR. Resveratrol abrogates adhesion molecules and protects against TNBS-induced ulcerative colitis in rats. Can J Physiol Pharmacol. 2011;89(11):811–8.PubMedGoogle Scholar
- Liu X, Wang J. Anti-inflammatory effects of iridoid glycosides fraction of folium syringae leaves on TNBS-induced colitis in rats. J Ethnopharmacol. 2011;133(2):780–7.View ArticlePubMedGoogle Scholar
- Xu X, Xu C, Saud SM, Lu X, Liu L, Fang L, Zhang X, Hu J, Li W. Effect of Kuijie granule on the expression of TGF-beta/Smads signaling pathway in patients with ulcerative colitis. Evid Based Complement Alternat Med. 2016;2016:2601830.PubMedPubMed CentralGoogle Scholar
- Jia Y, Guan Q, Jiang Y, Salh B, Guo Y, Tu P, Du C. Amelioration of dextran sulphate sodium-induced colitis in mice by echinacoside-enriched extract of Cistanche Tubulosa. Phytother Res. 2014;28(1):110–9.View ArticlePubMedGoogle Scholar
- CC DG, Xianjing F, Chungang Z, Shikai: Z: Clinical Observation on Modified Pulsatilla Decoction for Enema Treating Acute Period of Ulcerative Colitis of Left Hemicolon Type 中医杂志 2015(21):1862–1866.Google Scholar
- Chen Bin ZK, Liu F. Experience summary about treatment of ulcerative colitis. Journal of New Chinese Medicine. 2011;43(10):139–41.Google Scholar
- Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007;2(3):541–6.View ArticlePubMedGoogle Scholar
- Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 1989;96(3):795–803.View ArticlePubMedGoogle Scholar
- Xiao HT, Lin CY, Ho DH, Peng J, Chen Y, Tsang SW, Wong M, Zhang XJ, Zhang M, Bian ZX. Inhibitory effect of the gallotannin corilagin on dextran sulfate sodium-induced murine ulcerative colitis. J Nat Prod. 2013;76(11):2120–5.View ArticlePubMedGoogle Scholar
- Tsang SW, Ip SP, Wu JC, Ng SC, Yung KK, Bian ZX. A Chinese medicinal formulation ameliorates dextran sulfate sodium-induced experimental colitis by suppressing the activity of nuclear factor-kappaB signaling. J Ethnopharmacol. 2015;162:20–30.View ArticlePubMedGoogle Scholar
- Malik T, Mannon P. Inflammatory bowel diseases: emerging therapies and promising molecular targets. Front Biosci (Schol Ed). 2012;4:1172–89.Google Scholar
- Khanna PV, Shih DQ, Haritunians T, McGovern DP, Targan S. Use of animal models in elucidating disease pathogenesis in IBD. Semin Immunopathol. 2014;36(5):541–51.View ArticlePubMedPubMed CentralGoogle Scholar
- te Velde AA, Verstege MI, Hommes DW. Critical appraisal of the current practice in murine TNBS-induced colitis. Inflamm Bowel Dis. 2006;12(10):995–9.View ArticleGoogle Scholar
- Muzes G, Molnar B, Tulassay Z, Sipos F. Changes of the cytokine profile in inflammatory bowel diseases. World J Gastroenterol: WJG. 2012;18(41):5848–61.View ArticlePubMedPubMed CentralGoogle Scholar
- Neuman MG. Signaling for inflammation and repair in inflammatory bowel disease. Rom J Gastroenterol. 2004;13(4):309–16.PubMedGoogle Scholar
- Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000;51:289–98.View ArticlePubMedGoogle Scholar
- Atreya I, Atreya R, Neurath MF. NF-kappaB in inflammatory bowel disease. J Intern Med. 2008;263(6):591–6.View ArticlePubMedGoogle Scholar
- Lee SY, Jeong JJ, Eun SH, Kim DH. Anti-inflammatory effects of ginsenoside Rg1 and its metabolites ginsenoside Rh1 and 20(S)-protopanaxatriol in mice with TNBS-induced colitis. Eur J Pharmacol. 2015;762:333–43.View ArticlePubMedGoogle Scholar
- Spehlmann ME, Eckmann L. Nuclear factor-kappa B in intestinal protection and destruction. Curr Opin Gastroenterol. 2009;25(2):92–9.View ArticlePubMedGoogle Scholar
- Franke TF, Kaplan DR, Cantley LC, Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science. 1997;275(5300):665–8.View ArticlePubMedGoogle Scholar
- Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy--from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta. 2005;1754(1–2):253–62.View ArticlePubMedGoogle Scholar
- Carter AB, Hunninghake GW. A constitutive active MEK --> ERK pathway negatively regulates NF-kappa B-dependent gene expression by modulating TATA-binding protein phosphorylation. J Biol Chem. 2000;275(36):27858–64.PubMedGoogle Scholar
- Khare V, Dammann K, Asboth M, Krnjic A, Jambrich M, Gasche C. Overexpression of PAK1 promotes cell survival in inflammatory bowel diseases and colitis-associated cancer. Inflamm Bowel Dis. 2015;21(2):287–96.View ArticlePubMedPubMed CentralGoogle Scholar